Analyst Price Target is $65.86
▲ +40.54% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Akero Therapeutics in the last 3 months. The average price target is $65.86, with a high forecast of $83.00 and a low forecast of $58.00. The average price target represents a 40.54% upside from the last price of $46.86.
Current Consensus is
The current consensus among 8 investment analysts is to buy stock in Akero Therapeutics. This Buy consensus rating has held steady for over two years.
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.